NEW YORK (GenomeWeb News) – Molecular Detection today said that it has raised $3.3 million through a Series C financing, which it will use to support the launch of its rapid, molecular Staphylococcus aureus test.

In addition to the financing, Molecular Detection said that it has named Todd Wallach to serve as CEO of the firm. Wallach previously was CFO of Aton Pharma and was a VP of finance at Acquity Pharmaceuticals, before that firm was acquired by Opko Health.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.